NCT07530094 2026-04-15
STELLAR01
Jiangsu Cancer Institute & Hospital
Phase 2 Recruiting
Clinical Trials
11 trialsNCT06869226 2025-10-02
A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT06231680 2024-03-29
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Phase 2 Unknown
NCT05624099 2023-10-19
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Fujian Cancer Hospital
Phase 2 Recruiting
NCT05637268 2022-12-05
Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05476380 2022-07-27
Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04390945 2022-02-03
Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer
The First Affiliated Hospital of Henan University of Science and Technology
Phase 2 Unknown
NCT05183958 2022-01-11
A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04286958 2021-12-10
ESCC
Hebei Medical University Fourth Hospital
Phase 2 Unknown
NCT03187314 2020-08-17
Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer
Hangzhou Cancer Hospital
Phase 2 Completed
NCT04512417 2020-08-13
A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown